Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy

ConclusionThe study showed that esketamine may be a cost-effective opportunity from the societal perspective for the management of patients with treatment-resistant depression. In the future, data collected from observational studies or registries, which can include the collection of productivity losses and also costs sustained by the patients, will be able to provide further evidence in order to improve the reliability of the model results.
Source: PharmacoEconomics - Category: Health Management Source Type: research